A Phase II Vaccine Dose Finding Pilot Study for Development of an Anti-Influenza A (H5N1) Intravenous Hyper-Immune Globulin.
Phase of Trial: Phase II
Latest Information Update: 07 Aug 2018
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary)
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions
- 21 Apr 2016 Status changed from active, no longer recruiting to discontinued.
- 08 Mar 2012 Additional lead trial investigator (H. Clifford Lane, M.D) identified as reported by ClinicalTrials.gov.
- 16 Aug 2011 Planned end date changed from 1 Mar 2010 to 1 May 2013 as reported by ClinicalTrials.gov.